A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

PURPOSE: Accumulating analyses of pro-oncogenic molecular mechanisms triggered a rapid development of targeted cancer therapies. Although many of these treatments produce impressive initial responses, eventual resistance onset is practically unavoidable. One of the main approaches for preventing thi...

Descripción completa

Detalles Bibliográficos
Autores principales: El Zawily, Amr, Vizeacoumar, Frederick S., Dahiya, Renuka, Banerjee, Sara L., Bhanumathy, Kalpana K., Elhasasna, Hussain, Hanover, Glinton, Sharpe, Jessica C., Sanchez, Malkon G., Greidanus, Paul, Stacey, R. Greg, Moon, Kyung-Mee, Alexandrov, Ilya, Himanen, Juha P., Nikolov, Dimitar B., Fonge, Humphrey, White, Aaron P., Foster, Leonard J., Wang, Bingcheng, Toosi, Behzad M., Bisson, Nicolas, Mirzabekov, Tajib A., Vizeacoumar, Franco J., Freywald, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Translational Cancer Mechanisms and Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345963/
https://www.ncbi.nlm.nih.gov/pubmed/36976175
http://dx.doi.org/10.1158/1078-0432.CCR-22-2535

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345963/
https://www.ncbi.nlm.nih.gov/pubmed/36976175
http://dx.doi.org/10.1158/1078-0432.CCR-22-2535

Ejemplares similares